MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40164-024-00484-9

Медицинская библиотека · Experimental hematology & oncology · 2024

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Yan Fangfang, Jiang Vivian, Jordan Alexa, Che Yuxuan, Liu Yang, Cai Qingsong, Xue Yu, Li Yijing, McIntosh Joseph, Chen Zhihong, Vargas Jovanny, Nie Lei, Yao Yixin, Lee Heng-Huan, Wang Wei, Bigcal JohnNelson R, Badillo Maria, Meena Jitendra, Flowers Christopher, Zhou Jia, Zhao Zhongming, Simon Lukas M, Wang Michael

СтатьяПеревод в очереди

Аннотация

Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton's tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes. To dissect the underlying mechanisms of sequential resistance to BTKi and CAR-T therapy, we performed single-cell RNA sequencing analysis for 66 samples from 25 patients treated with BTKi and/or CAR-T therapy and conducted in-depth bioinformatics™ analysis. Our analysis revealed that MYC activity progressively increased with sequential resistance. HSP90AB1 (Heat shock protein 90 alpha family class B member 1), a MYC target, was identified as early driver of CAR-T resistance. CDK9 (Cyclin-dependent kinase 9), another MYC target, was significantly upregulated in Dual-R samples. Both HSP90AB1 and CDK9 expression were correlated with MYC activity levels. Pharmaceutical co-targeting of HSP90 and CDK9 synergistically diminished MYC activity, leading to potent anti-MCL activity. Collectively, our study revealed that HSP90-MYC-CDK9 network is the primary driving force of therapeutic resistance.

Для цитирования: Yan Fangfang, Jiang Vivian, Jordan Alexa, Che Yuxuan, Liu Yang, Cai Qingsong, Xue Yu, Li Yijing, McIntosh Joseph, Chen Zhihong, Vargas Jovanny, Nie Lei, Yao Yixin, Lee Heng-Huan, Wang Wei, Bigcal JohnNelson R, Badillo Maria, Meena Jitendra, Flowers Christopher, Zhou Jia, Zhao Zhongming, Simon Lukas M, Wang Michael. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.. Experimental hematology & oncology. 2024. DOI: 10.1186/s40164-024-00484-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.